The use of base editing to generate universal off-the-shelf CAR T cells induced durable remissions -- up to 36 months in one ...

Expected rapid advances in CAR T and other cellular therapies may expand treatment options not only in cancer but also in ...

Cell-based immunotherapies have transformed cancer treatment, yet their widespread use remains constrained by safety risks, ...

Data presented at ASH 2025 suggest earlier-line use of cilta-cel leads to better outcomes in multiple myeloma because patients have fitter immune systems and less exhausted T cells, improving CAR T ...

Colleen Mabasa, a patient with multiple myeloma, discusses her CAR T-cell therapy journey and the pivotal role self-advocacy ...

Formerly Somite AI, the rebranded company aims to broaden the regenerative medicine landscape by building AI models that ...

Some parts of our bodies bounce back from injury in fairly short order. The outer protective layer of the eye—called the ...

Higher levels of CD4-positive naïve T cells in patients receiving CAR T-cell therapy for multiple myeloma are associated with ...

The American Society of Gene & Cell Therapy (ASGCT), the leading professional organization for the advancement of cell and gene therapies (CGTs), and the Orphan Therapeutics Accelerator (OTXL), a ...

A blood cancer diagnosis comes with a lot of new information and confusion ranging from blood tests and medical terminology to healthcare provider conversations and treatment considerations. Here’s ...

Burkitt's lymphoma is a rare and aggressive blood cancer characterized by a translocation of the MYC gene. It occurs most ...

In patients with relapsed or refractory systemic lupus erythematosus, allogeneic CAR-NK cell therapy may offer a safe ...